Trial Profile
A study evaluating effect of Pembrolizumab or Nivolumab on immune biomarkers in peripheral blood monocularcells.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 08 Nov 2017 New trial record
- 18 Oct 2017 Results (n=19) presented at the 18th World Conference on Lung Cancer